Bert van Meurs Shares the New Late-breaking Results from the iMODERN Trial
Bert van Meurs, Chief Business Leader Image Guided Therapy and Member of the Executive Committee at Royal Philips, shared on LinkedIn:
”New late-breaking results from the iMODERN trial, presented at TCT 2025, bring important clarity for heart attack patients with multi-vessel disease.
This global study confirms that treating additional lesions during the initial procedure is just as safe as waiting to stage treatment, giving clinicians more flexibility to tailor care to each patient’s needs.
Complementary findings from the ILIAS ANOCA study also highlight the value of physiology-guided assessment and personalized therapy for patients with angina but no obstructive coronary arteries, resulting in sustained improvements in quality of life.
I’m proud that Philips solutions supported both of these impactful studies.
Together with our clinical partners, we’re helping advance evidence-based, individualized cardiovascular care for patients worldwide.”
Read the full announcement here.
Stay updated on all scientific advances with Hemostasis Today.
-
Dec 19, 2025, 13:30PPTA Europe’s Holiday Message: Wishing Health, Rest, and Renewal for 2026
-
Dec 19, 2025, 13:22If You Were Reading a “Bible for Blood Donation Volunteers,” What’s the ONE Thing That Must Be in It?
-
Dec 19, 2025, 12:52Julia Owens: Stroke Remains One of the World’s Leading Causes of Death and Disability
-
Dec 19, 2025, 12:03Pradeep Natarajan: Our New Genetic Study of Aortic Stenosis in ~3M
-
Dec 19, 2025, 11:47ESO Blog: Anna Gardin on Stroke Risk in the Era of Climate Extremes
-
Dec 19, 2025, 10:51Sarah Elkourashy Presents Insights on Caplacizumab for TTP at ASH25
-
Dec 19, 2025, 10:08Camilla Lombardi Shares an EHC Nutrition Guide for People with Bleeding Disorders
-
Dec 19, 2025, 09:56Danny Hsu Shares The ”I-WISh” Study by Nichola Cooper on ITP
-
Dec 19, 2025, 09:39Paul Bolaji: A Landmark Achievement -The Historic 1st Nigerian Stroke Leaders’ Summit 2025